Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial

Vamsi K. Kota, Michael W. Deininger, Jason H. Mendler, Wei Shen, Erinn Hoag Goldman, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 6798–6799.

https://doi.org/10.1182/blood-2022-162428

Published: 2022

Journal Articles

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Jennifer Brudno, MD, Steven Hartman, Norris Lam, BS, David F. Stroncek, John M. Rossi, MS, Yueh-wei Shen, Allen Xue, PhD, Adrian Bot, MD PhD, Jennifer A Kanakry, MD, Steven Z. Pavletic, MD, Lekha Mikkilineni, MD, Mark Roschewski, MD, Robert M. Dean, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Steve A. Rosenberg, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2018) 132 (Supplement 1): 697.

https://doi.org/10.1182/blood-2018-99-113731

Published: 2018

Journal Articles

Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL

John Rossi, Patrick Paczkowski, Yueh-Wei Shen, Kevin Morse, Brianna Flynn, Alaina Kaiser, Colin Ng, Kyle Gallatin, Tom Cain, Rong Fan, Sean Mackay, James R. Heath, Steven A. Rosenberg, James N. Kochenderfer, Jing Zhou, Adrian Bot

Blood (2018) 132 (8): 804–814.

https://doi.org/10.1182/blood-2018-01-828343

Published: 2018

Includes: Supplemental data

Journal Articles

Using a Next Generation Sequencing Panel to Discover the Obscure Causes of Hereditary Hemolytic Anemias

Archana M Agarwal, MD, N. Scott Reading, PhD, Kimberly Frizzell, PhD, Wei Shen, PhD, Shelly Sorrells, PhD, Mohamed E Salama, MD, Josef T. Prchal, MD, Hassan M. Yaish, Jay L Patel, MD, Robert D. Christensen, MD

Blood (2016) 128 (22): 2433.

https://doi.org/10.1182/blood.V128.22.2433.2433

Published: 2016

Journal Articles

Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

John M. Rossi, MS, Sattva S. Neelapu, MD, William Y. Go, MD PhD, Yueh-wei Shen, MS, Marika Sherman, MS, Frederick L. Locke, MD, Nancy L Bartlett, MD, Tanya Siddiqi, MD, Lynn Navale, MS, Meg Elias, RN,BSN, Jeff Wiezorek, MD MS, Adrian Bot, MD PhD

Blood (2015) 126 (23): 2730.

https://doi.org/10.1182/blood.V126.23.2730.2730

Published: 2015

Journal Articles

Targeted Detection of Copy Number Variants Using a Myeloid Malignancy Next Generation Sequencing Mutation Panel Allows Comprehensive Genetic Analysis Using a Single Testing Method

Wei Shen, PhD, Philippe Szankasi, PhD, Maria Sederberg, MS, Jonathan Schumacher, MS, Kimberly Frizzell, PhD, Elaine P Gee, PhD, Jay L Patel, MD, Sarah T. South, PhD, Xinjie Xu, PhD, Todd W Kelley, MD

Blood (2015) 126 (23): 2887.

https://doi.org/10.1182/blood.V126.23.2887.2887

Published: 2015

Journal Articles

Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy

Arianne Perez, PhD, Lynn Navale, MS, John M. Rossi, MS, Yueh-wei Shen, MS, Yizhou Jiang, PhD, Marika Sherman, MS, Armen Mardiros, PhD, Sean C. Yoder, MS, William Y. Go, MD PhD, Steven A. Rosenberg, MD PhD, Jeff Wiezorek, MD MS, Margo R. Roberts, PhD, David D. Chang, MD PhD, James N. Kochenderfer, MD, Adrian Bot, MD PhD

Blood (2015) 126 (23): 2042.

https://doi.org/10.1182/blood.V126.23.2042.2042

Published: 2015

Journal Articles

Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy

Adrian Bot, MD PhD, John M. Rossi, MS, Yizhou Jiang, PhD, Lynn Navale, MS, Yueh-wei Shen, MS, Marika Sherman, MS, Armen Mardiros, PhD, Sean C. Yoder, MS, William Y. Go, MD PhD, Steven A. Rosenberg, MD PhD, Jeff Wiezorek, MD MS, David D. Chang, MD PhD, James N. Kochenderfer, MD, Margo R. Roberts, PhD

Blood (2015) 126 (23): 4426.

https://doi.org/10.1182/blood.V126.23.4426.4426

Published: 2015

NARROW

Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL

Using a Next Generation Sequencing Panel to Discover the Obscure Causes of Hereditary Hemolytic Anemias

Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Targeted Detection of Copy Number Variants Using a Myeloid Malignancy Next Generation Sequencing Mutation Panel Allows Comprehensive Genetic Analysis Using a Single Testing Method

Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy

Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only